🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 72 of 114

  1. Placebo for empasiprubart- solution for IV infusion, ARGX-117

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  2. Placebo for fezolinetant film-coated tablets 45 mg, fezolinetant

    Astellas Pharma GmbH

    Moderate to Severe Vasomotor Symptoms (VMS)

    phase 3 small molecule active

    1 trial

  3. Placebo for glepaglutide, Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  4. Placebo for mepolizumab is a 0.9% sodium chloride solution in a syringe for subcutaneous injection., PREDNISOLONE, MEPOLIZUMAB, METHYLPREDNISOLONE, PREDNISONE, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    phase 3 small molecule active

    1 trial

  5. Placebo for pembrolizumab, ENZALUTAMIDE , PEMBROLIZUMAB

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  6. Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  7. Placebo for risankizumab 300mg/3.33ml solution for infusion, ABBV-066 / Risankizumab, Placebo for Risankizumab 90mg/mL Solution for injection in Pre-filled Syringe, Risankizumab, ABBV-066, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  8. Placebo for risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial

  9. Placebo in combination with Cytarabine Injection

    Moleculin Biotech

    Acute Myeloid Leukaemia (AML)

    phase 3 small molecule active

    1 trial

  10. Placebo injection, 0.8 ml is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in water for injection (wfi) intended for subcutaneous injection, ISIS 678354

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia.

    phase 3 small molecule active

    1 trial

  11. Placebo injections

    Centocor B.V.

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  12. Placebo intramuscular injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Spontaneous Uriticaria

    phase 3 small molecule active

    1 trial

  13. Placebo is 0.9% (w/v) NaCl for injection and is to be provided by sites., IVX-A12

    AstraZeneca AB

    Respiratory Syncytial Virus and Human Metapneumovirus

    phase 3 small molecule active

    1 trial

  14. Placebo is a solution for infusion of human albumin 1%, is an albumin preparation manufactured by dilution from the drug product of Albiomin 20%, it will be administrated via intravenous infusion., Trimodulin (human IgM, IgA, IgG solution)

    Biotest Pharma GmbH

    Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule active

    1 trial

  15. Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration., Skyrizi 150 mg solution for injection in pre-filled syringe, Sonelokimab, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis

    phase 3 small molecule active

    1 trial

  16. Placebo is identical to the active NMRA-335140 but without the active drug substance to maintain study blinding., NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  17. Placebo is identical to the active drugs but without the active drug substance to maintain study blinding. Niraparib placebo tablets, Dostarlimab placebo infusion bags, JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  18. Placebo is solution for injection (150 mg/ml) contained in vials equal to those of Canakinumab and appears identical to the Test product. Placebo is provided by Novartis pharma., Ilaris 150 mg/ml solution for injection

    Istituto Gentili S.r.l.

    PAPA syndrome

    phase 3 small molecule active

    1 trial

  19. Placebo liquid formulation will be indistinguishable from its tasimelteon counterpart and will be administered in the same way., Tasimelteon

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  20. Placebo matching < Staccato® alprazolam > and without active substance, alprazolam

    Lacuna Pharma Pty Ltd

    Stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  21. Placebo matching AMX0035, AMX0035

    Lacuna Pharma Pty Ltd

    Progressive Supranuclear Palsy

    phase 3 small molecule active

    1 trial

  22. Placebo matching BI 1015550, BI 1015550, BI 1015550

    Boehringer Ingelheim

    Interstitial lung diseases, Familial pulmonary fibrosis, Pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  23. Placebo matching BI 1291583, BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  24. Placebo matching DNTH103, DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

  25. Placebo matching IMP., Vyvgart 1 000 mg solution for injection in pre-filled syringe

    argenx

    Primary Sjögren’s Disease

    phase 3 small molecule active

    1 trial

  26. Placebo matching Obicetrapib 10 mg tablets, Obicetrapib, Placebo matching Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  27. Placebo matching Ozanimod hard-gelatin capsules, Ozanimod, Ozanimod

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  28. Placebo matching REGN7508, REGN7508

    Lacuna Pharma Pty Ltd

    Cancer-Associated Thrombosis (CAT).

    phase 3 small molecule active

    1 trial

  29. Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized), ustekinumab, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (authorized - MA number: 6697366.00.00), bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  30. Placebo matching to garetosmab, Garetosmab

    Lacuna Pharma Pty Ltd

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

  31. Placebo matching to spesolimab

    Boehringer Ingelheim

    Pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  32. Placebo of BELAPECTIN, BELAPECTIN

    GALECTIN THERAPEUTICS INC

    Esophageal Varices in NASH Cirrhosis

    phase 3 small molecule active

    1 trial

  33. Placebo of Eliquis 2.5 mg, Eliquis 2.5 mg film-coated tablets

    Pari Pharma GmbH

    Intrahepatic non-cirrhotic portal hypertension

    phase 3 small molecule active

    1 trial

  34. Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg

    Amneal Pharma Europe Ltd

    Uncomplicated Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  35. Placebo of Procoralan 5 mg, Procoralan 5 mg film-coated tablets

    Pari Pharma GmbH

    Septic shock

    phase 3 small molecule active

    1 trial

  36. Placebo of XEOMIN 100UY, powder for injection, XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    incisional hernia

    phase 3 small molecule active

    1 trial

  37. Placebo of ZIMINO (glucose 5%), ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation

    phase 3 small molecule active

    1 trial

  38. Placebo of Zodasiran, ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia (HoFH)

    phase 3 small molecule active

    1 trial

  39. Placebo pMDI to match budesonide/formoterol fumarate pMDI, PREDNISOLONE, Placebo MDI to match to Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, SALBUTAMOL, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension

    AstraZeneca AB

    Severe and inadequately controlled asthma

    phase 3 small molecule active

    1 trial

  40. Placebo solution for IV infusion, ARGX-117, HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo solution for IV infusion, HUMAN NORMAL IMMUNOGLOBULIN (IV)

    argenx

    Multifocal Motor Neuropathy

    phase 3 small molecule active

    1 trial

  41. Placebo tablet matching acetylsalicylic acid, MIGOUTINE 0,5 mg, comprimé pelliculé, ACETYLSALICYLIC ACID , Placebo tablet matching migoutine 0,5 mg, comprimé pelliculé

    The George Institute

    Type 2 diabetic patients with no prior cardiovascular (CV) events

    phase 3 small molecule active

    1 trial

  42. Placebo tablets to match S95032 drug product are supplied as film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    Ningbo Cancer Hospital

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  43. Placebo tablets to match S95032 drug product are supplied as white to off-white, round (10 mg) and white to off-white oblong (40 mg) film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    The George Institute

    Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

    phase 3 small molecule active

    1 trial

  44. Placebo tablets without active pharmaceutical ingredient closely resembling the imp, Hetrombopag Olamine

    Lacuna Pharma Pty Ltd

    Chemotherapy induced thrombocytopenia

    phase 3 small molecule active

    1 trial

  45. Placebo tablets, ELENESTINIB, ELENESTINIB, ELENESTINIB, ELENESTINIB

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis and SSM

    phase 3 small molecule active

    1 trial

  46. Placebo tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Small cell lung cancer (SCLC)

    phase 3 small molecule active

    1 trial

  47. Placebo to 100mg masitinib, Placebo to 200mg masitinib, masitinib, masitinib

    AB Science

    Mastocytosis

    phase 3 small molecule active

    1 trial

  48. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.